Iter-4360dd15-0100-human-trial-vs-non-original-screening-of-38310895-references

PMID 38310895 参考文献的“原始人体试验 / 非原始试验”复核（第 100 轮）

本轮只做一件事：把上一轮从 PMID 38310895 的 Europe PMC 参考文献里抽出来的一批候选 PMID，用 PubMed 逐条复核为“原始人体试验 / 非原始试验”。

复核方法

# 先以前轮抽取的候选 PMID 为种子。
# 再用 PubMed 逐条确认题名、期刊与研究设计词。
# 判据：题名明确出现 follow-up、longitudinal analysis、extension、ancillary、postextension 时，优先判为 非原始试验；其余 interventional / randomized / pilot / phase I/II/III 研究且为首次报告者，判为 原始人体试验。

本轮已复核的 PMID

原始人体试验（但不一定是长寿相关）

* 33977284 — Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
* 29408453 — A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
* 32475067 — Dose-Dependent Acute Effects of Everolimus Administration on Immunological, Neuroendocrine and Psychological Parameters in Healthy Men
* 35040506 — mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis
* 25525171 — Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial
* 24618547 — Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial
* 18037627 — Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
* 27613521 — Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
* 29992557 — Efficacy and safety of everolimus plus exemestane ... 4EVER trial
* 22115710 — A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema
* 20847709 — A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization
* 22959478 — Rapamycin does not affect post-absorptive protein metabolism in human skeletal muscle
* 19188252 — Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis
* 24691032 — Activation of mTORC1 signaling and protein synthesis in human muscle following blood flow restriction exercise is inhibited by rapamycin
* 22367193 — A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults

非原始试验 / 需要排除出“原始试验”清单

* 31781682 — Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial

这轮的整洁结论

# PMID 31781682 应排除：题名已明确是 follow-up，不是首次原始报告。
# 其余已复核 PMID 目前都可算作 原始人体研究，但大多数是 安全性 / 机制 / 疾病特异性 试验，并不是“抗衰老终点”的直接证据。
# 因此，后续整理时应把“原始人体试验”与“长寿相关试验”拆成两个独立标签，避免把机制研究误记为抗衰老试验。

可复现入口

* Europe PMC 参考文献接口：https://www.ebi.ac.uk/europepmc/webservices/rest/MED/38310895/references/1/1000
* PubMed 逐条检索 PMID 后复核题名与研究设计词。